SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[Skystar to Present at the Brean Murray Carret & Co. 2009 China Growth Conference XI'AN, CHINA — November 11 , 2009 — Skystar Bio-Pharmaceutical Company skystar@tpg-ir.com To request a one-on-one meeting or to be added to Skystar’s email list, please contact Brandi Floberg at About Skystar Bio-Pharmaceutical Company http://www.skystarbio-pharmaceutical.com Skystar is a China-based developer and distributor of veterinary healthcare and]

By | 2016-03-01T07:00:23+00:00 November 12th, 2009|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: Skystar to Present at the Brean Murray Carret

[Skystar to Present at the Brean Murray Carret & Co. 2009 China Growth Conference XI'AN, CHINA — November 11 , 2009 — Skystar Bio-Pharmaceutical Company skystar@tpg-ir.com To request a one-on-one meeting or to be added to Skystar’s email list, please contact Brandi Floberg at About Skystar Bio-Pharmaceutical Company http://www.skystarbio-pharmaceutical.com Skystar is a China-based developer and distributor of veterinary healthcare and]

By | 2016-03-01T07:02:25+00:00 November 12th, 2009|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: (Original Filing)

[FORM 10-Q x September 30, 2009 For the quarterly period ended o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________ to _____________ 333-147363 BIOSTAR PHARMACEUTICALS, INC. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Road, Xianyang, Shaanxi Province, The People’s Republic] [I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By | 2016-03-03T15:34:54+00:00 November 12th, 2009|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments

BSPM [Biostar Pharmaceuticals,] 10-Q: FORM 10-Q x September 30, 2009 For the

[FORM 10-Q x September 30, 2009 For the quarterly period ended o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from ______________ to _____________ 333-147363 BIOSTAR PHARMACEUTICALS, INC. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Road, Xianyang, Shaanxi Province, The People’s Republic] [I, Ronghua Wang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Elaine Zhao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Biostar Pharmaceuticals, Inc. (the "Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Ronghua Wang Chief Executive Officer EX-32.1 4 ex32-1.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. Elaine Zhao Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 5 ex32-2.htm]

By | 2016-03-03T15:35:58+00:00 November 12th, 2009|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

JST [JINPAN INTERNATIONAL] CORRESP: (Original Filing)

[JINPAN INTERNATIONAL LIMITED November 12, 2009 Via Edgar and Federal Express Jay Mumford Senior Attorney 100 F Street, N.E. Mail Stop 6010 Re: Jinpan International Limited Form 20-F for the Fiscal Year Ended December 31, 2008 Filed June 10, 2009 File No. 001-14742 Dear Mr. Mumford: Set forth herein are our responses to the comments in the letter (the “]

JST [JINPAN INTERNATIONAL] CORRESP: JINPAN INTERNATIONAL LIMITED November 12, 2009 Via Edgar

[JINPAN INTERNATIONAL LIMITED November 12, 2009 Via Edgar and Federal Express Jay Mumford Senior Attorney 100 F Street, N.E. Mail Stop 6010 Re: Jinpan International Limited Form 20-F for the Fiscal Year Ended December 31, 2008 Filed June 10, 2009 File No. 001-14742 Dear Mr. Mumford: Set forth herein are our responses to the comments in the letter (the “]

Skip to toolbar